Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 6Breast Neoplasms, Male 3Testicular Neoplasms 2Testicular Germ Cell Tumor 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Uterine Cervical Neoplasms 1Teratoma 1Seminoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neutropenia 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Lymphoma, Follicular 1Lymphoma, AIDS-Related 1Inflammatory Breast Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1Endodermal Sinus Tumor 1Central Nervous System Neoplasms 1Carcinoma, Embryonal 1

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1merphos 1durvalumab 1Vinblastine 1Specimen Handling 1Platinum 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Doxorubicin 1Disulfides 1Cisplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Renal Pelvis and Ureter Urothelial Carcinoma × pegfilgrastim × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡